ÂÜÀòÂÒÂ×

Dr. Alexander Michkov is a co-founder and Chief Scientific Officer (CSO)/Chief Operating Officer (COO) of NeyroblastGX. He earned his Ph.D. from the University of California, Riverside (UCR) in Molecular Genetics, Genomics, and Bioinformatics. Dr. Michkov was a postdoctoral scientist at the University of California, San Diego (UCSD), where he studied expression patterns of human GPCRs and G-protein signaling pathways in lung tissue and the primary pulmonary cell cultures. Dr. Michkov worked in the UCSD- Bristol-Myers Squibb joint project on the discovery of disease-relevant GPCR targets and therapeutics using a combination of GPCR expression data with validation studies (e.g., signaling and functional activities assays). He initiated a project for a more precise prediction of GPCR protein amounts by measuring translated mRNA using Polysome Profiling Analysis. He has various research publications and presentations related to genome editing, RNA/DNA sequencing, G-protein signaling, and the discovery of new therapeutic targets (GPCR).